| Literature DB >> 26525086 |
V Larouche1, L Snell2, D V Morris3.
Abstract
UNLABELLED: Myxoedema madness was first described as a consequence of severe hypothyroidism in 1949. Most cases were secondary to long-standing untreated primary hypothyroidism. We present the first reported case of iatrogenic myxoedema madness following radioactive iodine ablation for Graves' disease, with a second concurrent diagnosis of primary hyperaldosteronism. A 29-year-old woman presented with severe hypothyroidism, a 1-week history of psychotic behaviour and paranoid delusions 3 months after treatment with radioactive iodine ablation for Graves' disease. Her psychiatric symptoms abated with levothyroxine replacement. She was concurrently found to be hypertensive and hypokalemic. Primary hyperaldosteronism from bilateral adrenal hyperplasia was diagnosed. This case report serves as a reminder that myxoedema madness can be a complication of acute hypothyroidism following radioactive iodine ablation of Graves' disease and that primary hyperaldosteronism may be associated with autoimmune hyperthyroidism. LEARNING POINTS: Psychosis (myxoedema madness) can present as a neuropsychiatric manifestation of acute hypothyroidism following radioactive iodine ablation of Graves' disease.Primary hyperaldosteronism may be caused by idiopathic bilateral adrenal hyperplasia even in the presence of an adrenal adenoma seen on imaging.Adrenal vein sampling is a useful tool for differentiating between a unilateral aldosterone-producing adenoma, which is managed surgically, and an idiopathic bilateral adrenal hyperplasia, which is managed medically.The management of autoimmune hyperthyroidism, iatrogenic hypothyroidism and primary hyperaldosteronism from bilateral idiopathic adrenal hyperplasia in patients planning pregnancy includes delaying pregnancy 6 months following radioactive iodine treatment and until patient is euthyroid for 3 months, using amiloride as opposed to spironolactone, controlling blood pressure with agents safe in pregnancy such as nifedipine and avoiding β blockers.Autoimmune hyperthyroidism and primary hyperaldosteronism rarely coexist; any underlying mechanism associating the two is still unclear.Entities:
Year: 2015 PMID: 26525086 PMCID: PMC4626654 DOI: 10.1530/EDM-15-0087
Source DB: PubMed Journal: Endocrinol Diabetes Metab Case Rep ISSN: 2052-0573
Thyroid function tests
|
|
|
|
|
|---|---|---|---|
| July 23, 2014 | 0.03 | 21.1 | 6.8 |
| August 4, 2014 | 0.05 | 12.5 | 5.4 |
| October 8, 2014 | 0.30 | 14.4 | 3.8 |
| November 1, 2014 | >100 | <1.90 | 2.46 |
| November 11, 2014 | >100 | 6.30 | |
| December 17, 2014 | 18.15 | 12.10 | |
| January 5, 2015 | 28.90 | 11.10 | |
| March 4, 2015 | 5.79 | 16.20 | |
| April 9, 2015 | 3.80 | 14.90 | |
| May 15, 2015 | 2.93 | 17.60 |
Adrenal vein sampling results: March 23, 2015
|
|
|
|---|---|
| Cortisol IVC | 304 nmol/l |
| Cortisol LAV | 6928 nmol/l |
| Cortisol RAV | 7803 nmol/l |
| Selectivity index (cortisol RAV/IVC) | 25.66 (SI>3.0 denotes successful catheterization under ACTH stimulation) |
| Selectivity index (cortisol LAV/IVC) | 22.78 |
| Aldosterone IVC | 2277 pmol/l |
| Aldosterone LAV | 336 851 pmol/l |
| Aldosterone RAV | 550 752 pmol/l |
| LAV aldosterone/cortisol ratio | 48.62 nmol/l per pmol per l |
| RAV aldosterone/cortisol ratio | 70.58 nmol/l per pmol per l |
| RAV/LAV A/C ratio (lateralization index) | 1.45:1 (4:1 is diagnostic for lateralization) |
IVC, inferior vena cava; LAV, left adrenal vein; RAV, right adrenal vein; SI, selectivity index.